» Articles » PMID: 34667003

Retrospective Analysis of Characteristics Associated with Higher-value Radiotherapy Episodes of Care for Bone Metastases in Medicare Fee-for-service Beneficiaries

Overview
Journal BMJ Open
Specialty General Medicine
Date 2021 Oct 20
PMID 34667003
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The Centers for Medicare & Medicaid Services' newly enacted Radiation Oncology Model ('RO Model') was designed to test the cost-saving potential of prospective episode-based payments for radiation treatment for 17 cancer diagnoses by encouraging high-value care and more efficient care delivery. For bone metastases, evidence supports the use of higher-value, shorter courses of radiation (≤10 fractions). Our goal was to determine the prevalence of short radiation courses (≤10 fractions) for bone metastases and the setting, treatment and patient characteristics associated with such courses and their expenditures.

Design: Using the RO Model episode file, we evaluated receipt of ≤10 fractions of radiotherapy for bone metastases and expenditures by treatment setting for Medicare fee-for-service beneficiaries during calendar years 2015-2017.Using unadjusted and adjusted regression models, we determined predictors of receipt of ≤10 fractions and expenditures. Multivariable models adjusted for treatment and patient characteristics.

Results: There were 48 810 episodes for bone metastases during the period. A majority of episodes for ≤10 fractions occurred in hospital-outpatient settings (62.8% (N=22 715)). After adjusting for treatment and patient factors, hospital-outpatient treatment setting remained a significant predictor of receiving ≤10 fractions (adjusted OR 2.03 (95% CI 1.95, 2.12; p<0.001) vs free-standing). The greatest adjusted contributors to total expenditures were number of fractions (US$-3424 (95% CI US$-3412 to US$-3435) for ≤10 fractions vs >10; p<0.001) and treatment type (including US$7716 (95% CI US$7424 to US$8018) for intensity modulated radiation therapy vs conventional external beam; p<0.001).

Conclusions: A measurable performance gap exists for delivery of higher-value bone metastases radiotherapy under an episode-based model, associated with increased expenditures. The RO Model may succeed in improving the value of bone metastases radiation. Increasing the capacity of free-standing centres to implement palliative-focused services may improve the ability of these practices to succeed under the RO Model.

References
1.
Spratt D, Mancini B, Hayman J, Boike T, Pierce L, Moran J . Contemporary Statewide Practice Pattern Assessment of the Palliative Treatment of Bone Metastasis. Int J Radiat Oncol Biol Phys. 2018; 101(2):462-467. PMC: 6844366. DOI: 10.1016/j.ijrobp.2018.02.037. View

2.
Chow R, Hoskin P, Chan S, Mesci A, Hollenberg D, Lam H . Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: A systematic review. Radiother Oncol. 2017; 122(3):323-331. DOI: 10.1016/j.radonc.2016.12.031. View

3.
Chang S, May P, Goldstein N, Wisnivesky J, Rosenzweig K, Morrison R . A Palliative Radiation Oncology Consult Service's Impact on Care of Advanced Cancer Patients. J Palliat Med. 2017; 21(4):438-444. PMC: 5867511. DOI: 10.1089/jpm.2017.0372. View

4.
Mills M, Solberg T, Halvorsen P . Centers for medicare & medicaid services radiation oncology alternative payment model and the future of radiation oncology physics practice. J Appl Clin Med Phys. 2020; 21(2):4-6. PMC: 7020974. DOI: 10.1002/acm2.12823. View

5.
Yu J, Pollack C, Herrin J, Zhu W, Soulos P, Xu X . Persistent Use of Extended Fractionation Palliative Radiotherapy for Medicare Beneficiaries With Metastatic Breast Cancer, 2011 to 2014. Am J Clin Oncol. 2019; 42(6):493-499. PMC: 6538429. DOI: 10.1097/COC.0000000000000548. View